Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital

2018 ◽  
Vol 25 (12) ◽  
pp. 1005-1005 ◽  
Author(s):  
Devin N Patel ◽  
Brian F Chapin ◽  
Stephen J Freedland
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Editorial Comment ◽  
Local Therapy ◽  
Equal Access ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Cancer Hospital

Prognostic impact of prior local therapy in castration-resistant prostate cancer

2021 ◽  
Author(s):  
Mikifumi Koura ◽  
Masaki Shiota ◽  
Shohei Ueda ◽  
Takashi Matsumoto ◽  
Satoshi Kobayashi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Local Therapy ◽  
Progression Free Survival ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Free Survival ◽  
First Line Therapy ◽  
Castration Resistant ◽  
Line Therapy

Abstract Objective This study aimed to reveal the prognostic values of prior local therapy in first-line therapy using androgen receptor-axis targeting agents (abiraterone or enzalutamide) or docetaxel for castration-resistant prostate cancer (CRPC). Methods The study included 303 patients treated with first-line therapy for non-metastatic and metastatic CRPC. The association between prior local therapy and therapeutic outcome including progression-free survival and overall survival was investigated by univariate and multivariate analyses as well as propensity score-matched analysis. Results In univariate analysis, local prior therapy was associated with a lower risk of all-cause mortality (hazard ratio, 0.56, 95% confidence interval, 0.40–0.79; P = 0.0009). Overall survival, but not progression-free survival, was better among patients with prior local therapy compared with patients without prior local therapy even after multivariate analysis and propensity score-matched analysis. Conclusions This study robustly indicated that prior local treatment was prognostic for overall survival among patients with CRPC. This finding is useful to predict patient prognosis in CRPC.

scholarly journals Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database

Cancer ◽  
2015 ◽  
Vol 122 (2) ◽  
pp. 222-229 ◽  
Author(s):  
Brian T. Hanyok ◽  
Lauren E. Howard ◽  
Christopher L. Amling ◽  
William J. Aronson ◽  
Matthew R. Cooperberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Equal Access ◽  
Castration Resistant Prostate Cancer ◽  
Hospital Database ◽  
Castration Resistant ◽  
Cancer Hospital

scholarly journals Predictors of skeletal‐related events and mortality in men with metastatic, castration‐resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

Cancer ◽  
2019 ◽  
Vol 125 (22) ◽  
pp. 4003-4010 ◽  
Author(s):  
Ingrid Lorese Tablazon ◽  
Lauren E. Howard ◽  
Amanda M. De Hoedt ◽  
William J. Aronson ◽  
Christopher J. Kane ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Equal Access ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Cancer Hospital ◽  
Skeletal Related Events

scholarly journals Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

2020 ◽  
Vol 12 ◽  
pp. 175883592097813
Author(s):  
Pernelle Lavaud ◽  
Clément Dumont ◽  
Constance Thibault ◽  
Laurence Albiges ◽  
Giulia Baciarello ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Androgen Receptor ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Next Generation ◽  
Castration Resistant Prostate Cancer ◽  
Free Survival ◽  
Castration Resistant ◽  
Recent Advances

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

Sign in / Sign up

Export Citation Format

Share Document